Strategic Acquisition Position Vectorious as a recently acquired asset by Edwards Lifesciences to leverage broader distribution channels, established sales force, and larger customer base in cardiovascular devices. Target cross-sell opportunities for V-LAP related monitoring within Edwards’ hospital networks and existing HF patient management offerings.

High Impact Market Capitalize on the unmet need in heart failure monitoring by offering implantable left atrial monitoring solutions that can reduce hospitalizations. Focus on hospitals and clinics pursuing advanced hemodynamic monitoring, leveraging Vectorious’ ongoing multi-region studies to build case studies for payer discussions.

Clinical Proof Emphasize VECTOR-HF I results and ongoing European, Israeli, and U.S. trials to support value-based selling. Develop collateral highlighting safety, ease of use, and accuracy to accelerate adoption among cardiology and HF teams, while aligning with Edwards Lifesciences’ clinical pathways.

Key Partners Target collaboration with large device players and distributors in cardiology and critical care, including potential integration with existing remote monitoring platforms. Propose bundled offerings that combine V-LAP data with comprehensive patient management and telemonitoring services.

Growth Ready Leverage modest but growing revenue and prior funding momentum to approach venture-backed and established stakeholders for strategic partnerships or co-development deals. Highlight scalability of the V-LAP platform and potential expansion into adjacent hemodynamic monitoring indications.